Non Clinical Development Officer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biotech s Developments In Race Against Rising Cancer Rates Revealed

Biotech s Developments In Race Against Rising Cancer Rates Revealed
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesSan antonioMatt coffeyThomas heinemanSusan galbraithDavidc mylesStephen kulischDaiichi sankyoIgor gorbatchevskyCelcuity incUnited nationsBaystreet media corpBiotech incOlema pharmaceuticals incOncolytics biotech incOncolytics biotech

Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate

OP-3136 demonstrated potent anti-tumor activity alone and in combination with both palazestrant and CDK4/6 inhibitors in preclinical ER+ breast cancer models Initiating IND-enabling studies with goal.

United statesSan franciscoUnited kingdomDavidc mylesGeoffrey mogilnerClinical developmentSecurities exchangeOlema pharmaceuticals incExchange commissionInternational conference on molecularDrug administrationChief discoveryNon clinical development officerMolecular targetsCancer therapeuticsInvestigational new drug

Olema Pharmaceuticals (OLMA) Reports KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity

Olema Pharmaceuticals (OLMA) Reports KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDavidc mylesClinical developmentOlema pharmaceuticals incInternational conference on molecularOlema pharmaceuticalsMolecular targetsCancer therapeuticsChief discoveryNon clinical development officer

Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity

Olema Oncology KAT6 Inhibitor Compounds Demonstrate Potent Anti-Tumor Activity
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoUnited kingdomDavidc mylesGeoffrey mogilnerInternational conference on molecularExchange commissionSecurities exchangeClinical developmentOlema pharmaceuticals incMolecular targetsCancer therapeuticsChief discoveryNon clinical development officerOlema oncologyolema oncologySecurities act

Olema Oncology Announces New Preclinical KAT6 Inhibitor Data to be Presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Olema Pharmaceuticals (NASDAQ:OLMA)

SAN FRANCISCO, Sept. 20, 2023 (GLOBE NEWSWIRE) Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology, NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and

United statesUnited kingdomSan franciscoGeoffrey mogilnerDavidc mylesOlema aurigeneClinical developmentOlema pharmaceuticals incInternational conference on molecularSecurities exchangeExchange commissionMolecular targetsCancer therapeuticsChief discoveryNon clinical development officerSecurities act